Job title: Chief Scientific Officer
Phil Skolnick has held leadership positions in industry, government and academia. Prior to joining Opiant, Dr. Skolnick served as the Director, Division of Therapeutics and Medical Consequences at the National Institute on Drug Abuse (2010-2017). He was Chief Scientific Officer (2001-2009) and President (2007-2009) of DOV Pharmaceutical, and a Lilly Research Fellow at Lilly Research Laboratories (1997-2000). He served as Senior Investigator and Chief, of the Laboratory of Neuroscience, NIH from 1986-1997. Dr. Skolnick has co-authored more than 550 publications in the fields of molecular and clinical neuropsychopharmacology. Dr. Skolnick received a BS from Long Island University (summa cum laude) and a PhD from the Department of Pharmacology, George Washington University School of Medicine. Among his awards and honors are an Anna Monika Prize, a Lifetime Achievement Award from the American Society of Clinical Psychopharmacology, and DSc (honoris causa) degrees from Long Island University and the University of Wisconsin-Milwaukee.
Live Q&A 6:50 pm
day: Day One
Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose 6:00 pm
Synthetic opioids like fentanyl now drive the opioid epidemic, responsible for more overdose deaths than both heroin and prescription opioids Nalmefene is a potent, long acting opioid antagonist; these properties make it especially well-suited to treat overdose caused by synthetic opioids OPNT 003 is a proprietary formulation of nalmefene nasal spray. The pharmacokinetic properties (Cmax…Read more
day: Day One